Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, ...
Neurology Advisor

Predicting Progression of Pure Autonomic Failure to Parkinson Disease

Pure autonomic failure may serve as a prodromal manifestation of Parkinson disease, Lewy body dementia, and multiple system atrophy.
Sunderland Echo on MSN

Washington woman's Everest trek to raise money in memory of much loved friend who passed away

Karen Joynson raised money for two charities close to her heart.

Australian musical theatre director Kellie Dickerson dies following battle with multiple system atrophy

Acclaimed Australian musical theatre director Kellie Dickerson has died after being diagnosed with a rare neurological ...
Medscape

Novel Iron-Lowering Drug Tied to Slowing of Multiple System Atrophy Progression

HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...
Medscape

Treatment of Multiple System Atrophy Using Intravenous Immunoglobulin

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia.
Monthly Prescribing Reference

Emrusolmin Fast Tracked for Multiple System Atrophy

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
European Medical Journal

MRI Marker Shows Promise for Progressive Supranuclear Palsy Diagnosis

A new MRI marker showed high accuracy for progressive supranuclear palsy diagnosis across international cohorts. Find out more.